Search

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

EHA25 Virtual | News Room

Welcome to the news room of EHA25 Virtual where you can find the most relevant news items.

Read more

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

EHA-RHS-ROHS Hematology Tutorial on Real World Challenges and Opportunities in Diagnostics and Management of Onco-hematological Patients Today

Dates: April 12-13, 2019
Location: Moscow, Russia
Chairs: P Sonneveld, I Poddubnaya, E Parovichnikova

Goal of the meeting
This 1,5 day meeting focuses on the most vital practical issues in oncohematology to teach the participants the appropriate and effective ways to use all the variety…

Read more